Vir Biotechnology's Hepatitis Delta Treatment Shows Promising Results in Phase 2 Trial, Positioning it as a Potential Rival to Gilead Sciences' Bulevirtide.

Vir Biotechnology's Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with its tobevibart-elebsiran combo, with no serious safety issues. Gilead's rival therapy bulevirtide has lower long-term response rates in earlier studies. The strong efficacy of Vir's therapy has drawn attention from retail traders, who highlight its potential for a future head-to-head Phase 3 matchup with Gilead.